注射用司妥昔单抗治疗中国特发性多中心Castleman病的成本效用分析

Cost-utility of siltuximab injection for idiopathic multicentric Castleman disease(iMCD)in China

司妥昔单抗是治疗罕见病特发性多中心Castleman病的创新药物,临床试验证明其具有确切的疗效和良好的安全性,但目前对于司妥昔单抗的经济学评价研究有限。本研究旨在基于现有临床资料以及公开发表数据,采用分区生存模型的分析方法,从医疗卫生体系的角度出发,评估司妥昔单抗组和安慰剂组终生治疗中国iMCD患者的平均治疗成本和健康产出,并进行价格阈值分析、增量分析结果与敏感性分析。研究发现司妥昔单抗组相比安慰剂组可增加6.31LYs和5.09QALYs。当WTP为242928元/QALY时,司妥昔单抗组相比安慰剂组具有经济性的最大价格阈值为8921.47元/瓶(400 mg)。因此,司妥昔单抗作为iMCD的一线治疗方式,相比安慰剂组,健康产出获益更高。

Siltuximab is an innovative drug used to treat idiopathic multicentric Castleman disease(iMCD),a rare condition.Clinical trials have demonstrated its efficacy and safety.However,there is limited research on the economic evaluation of siltuximab.Therefore,using a partition survival model,we aimed to evaluate the average treatment cost and health outcomes for Chinese patients with iMCD in the siltuximab group compared to the placebo group based on existing clinical and published data.We also conducted price threshold analysis,incremental cost-utility analysis,and sensitivity analysis.The results revealed that compared to the placebo group,the siltuximab group showed an increase of 6.31 life-years(LYs)and 5.09 quality-adjusted life-years(QALYs).At a willingness-to-pay(WTP)threshold of 242928 yuan/QALY,the maximum price threshold for siltuximab compared to the placebo group was 8921.47 yuan per bottle(400 mg).Therefore,as a first-line treatment for iMCD,siltuximab demonstrated superior health outcomes compared to placebo.